# iPSC

Neural Rewiring: Shanghai Biotech Secures Global First with Dual US-China Approval for Epilepsy Cell Therapy

Shanghai's Yuesai Biotechnology has become the first company globally to receive IND approval from both the US FDA and China's CDE for an iPSC-derived cell therapy targeting refractory epilepsy, marking a major breakthrough in regenerative medicine.